Characterisation of Asthma in Obese Subjects
Obese subjects with a physician's made diagnosis of asthma have a poorer asthma control than asthmatics with normal weight, less variability of peak expiratory flows (PEF) and bronchodilator response,increased induced sputum and systemic markers of inflammation and an increased prevalence of atopy.
Obese subjects have an increased incidence of co-morbidities such as rhinosinusitis, gastroesophageal reflux and sleep apnea syndrome.
This study aims to determine if, in comparison with asthmatics with a normal weight, paired for age and sex, obese subjects with asthma (all not using anti-inflammatory agents) show:
- A more uncontrolled asthma, increased health care use and poorer quality of life
- A reduced response to bronchodilators and diurnal variability of expiratory flows
- More marked airway inflammation and evidences of a systemic inflammatory response
- An increased prevalence of co-morbidities which can influence the report of respiratory symptoms or the severity of the disease, such as esophageal reflux symptoms, upper airway disease (rhinitis) and sleep apnea syndrome or other sleep disorder.
|Study Design:||Observational Model: Case Control
Time Perspective: Cross-Sectional
|Official Title:||Characterisation of Asthma in Obese Subjects. Relationships Between Asthma and Obesity, Potential Mechanisms by Which Obesity Can Contribute to Asthma and Modify Treatment Responses|
- Airway response to methacholine [ Time Frame: two weeks ]
- lung volumes [ Time Frame: Two weeks ]
Biospecimen Retention: Samples Without DNA
|Study Start Date:||August 2005|
|Study Completion Date:||July 2010|
Obese subjects with asthma (on inhaled bd only)
Non-obese subjects with asthma(on inhaled bd only)
Questionnaires on respiratory symptoms, health care use, quality of life, medication and asthma control will be administered and a thoracic examination performed.
Spirometry and bronchodilator response, blood tests for inflammatory parameters, pH measurements in exhaled air condensate and sputum induction will be performed. Peak expiratory flows will be measured and recorded on a diary card during one week.
On the second visit, measures of lung volumes and a methacholine challenge will be performed.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00532831
|Centre de Recherche, Hôpital Laval|
|Québec, Quebec, Canada, G1V 4G5|
|Principal Investigator:||Louis-Philippe Boulet, MD||Hôpital Laval|